I-MAB (IMAB) Price & Analysis

Q: When is I-Mab Adr’s upcoming earnings report date?

I-Mab Adr’s upcoming earnings report date is Nov 13, 2025 which is 31 days ago.

Q: How were I-Mab Adr’s earnings last quarter?

I-Mab Adr released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Q: Is I-Mab Adr overvalued?

According to Wall Street analysts I-Mab Adr’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does I-Mab Adr pay dividends?

I-Mab Adr does not currently pay dividends.

Q: What is I-Mab Adr’s EPS estimate?

I-Mab Adr’s EPS estimate is -0.04.

Q: What happened to I-Mab Adr’s price movement after its last earnings report?

I-Mab Adr reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Q: Which hedge fund is a major shareholder of I-Mab Adr?

Currently, no hedge funds are holding shares in IMAB

Compare

415 Followers

IMAB Stock Chart & Stats

$4.95

$0.18(18.08%)

At close: Jan 08 4:00 PM EST

$4.95

$0.18(18.08%)

Day’s Range― - ―

52-Week Range― - ―

Previous CloseN/A

Volume876.01K

Average Volume (3M)N/A

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)$165.61M

Total Debt (Recent Filing)$3.48M

Price to Earnings (P/E)―

BetaN/A

Next Earnings

Nov 13, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.34

Price to Sales (P/S)0.00

P/FCF Ratio-1.31

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.00

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentsI-Mab reported positive updated Phase 1 monotherapy results for givastomig, reinforcing the asset’s best in class profile in metastatic gastric cancer.

Global ExpansionI-Mab is accelerating development with a global randomized Phase 2 initiation and topline Ph1b expansion data release, creating near-term catalysts.

Market OpportunitiesGivastomig's design effectively doubles the addressable market by driving activity across CLDN18.2-low and PD-L1-low populations.

Bears Say

Corporate HistoryI-Mab has a history of corporate resets and program discontinuations or divestitures.

Market MisinterpretationI-Mab shares fell ~20% following a New York Times article, seen as an unwarranted mispricing due to the mischaracterization of I-Mab as a Chinese drugmaker.

Strategic UncertaintyThe strategic transformation introduces incremental uncertainty around capital allocation timing and governance focus.

I-MAB News

NovaBridge Biosciences Pursues Hong Kong Listing Amid Strategic Shift

I-MAB ( ($IMAB) ) has shared an update. NovaBridge Biosciences has filed an application for a dual primary...

1M ago

IMAB

One new option listing and two option delistings on October 30th

New option listings for October 30th include I-MAB American Depositary Shares (NBP). Option delistings effective October 30th include...

2M ago

HON

IMAB

NovaBridge Subsidiary Assigns VIS-101 License to Everest Medicines

An announcement from I-MAB ( ($IMAB) ) is now available. On October 28, 2025, NovaBridge Biosciences’ subsidiary, Visara,...

2M ago

IMAB

NovaBridge Biosciences Unveils New Identity and Strategic Direction

I-MAB ( ($IMAB) ) just unveiled an update. On October 24, 2025, shareholders of I-MAB approved a name...

2M ago

IMAB

I-Mab changes corporate name to NovaBridge Biosciences

NovaBridge (NBP) Biosciences has changed its corporate name from I-Mab (IMAB) to NovaBridge Biosciences. The change was overwhelmingly...

2M ago

IMAB

I-MAB Completes Acquisition of Bridge Health Biotech

I-MAB ( ($IMAB) ) has issued an announcement. On October 28, 2025, I-MAB announced the completion of its...

2M ago

IMAB

Promising Clinical Data and Strategic Uncertainties: Analyst Recommends ‘Buy’ for I-MAB

H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on IMAB stock, giving a Buy rating...

2M ago

IMAB

I-Mab Rebrands to NovaBridge Biosciences Following Shareholder Approval

An update from I-MAB ( ($IMAB) ) is now available. On October 24, 2025, I-Mab held an extraordinary...

2M ago

IMAB

I-MAB Releases Promising Phase I Data for Givastomig in Advanced Gastric Cancer

I-MAB ( ($IMAB) ) just unveiled an announcement. I-MAB has released updated data from its Phase I study...

2M ago

IMAB

I-MAB Reports Positive Phase I Results for Givastomig in Gastroesophageal Cancer

I-MAB ( ($IMAB) ) has provided an announcement. On October 23, 2025, I-MAB released updated results from its...

2M ago

IMAB

I-Mab Presents Promising Givastomig Data at 2025 Conference

I-MAB ( ($IMAB) ) just unveiled an announcement. I-Mab announced the presentation of updated Phase 1 data on...

2M ago

IMAB

Midday Fly By: Apple new F1 broadcast partner, CSX reports Q3 beat

The major averages were higher near noon as the U.S. government shutdown enters its seventeenth day with no...

2M ago

I-Mab Announces Strategic Transformation and Rebranding to NovaBridge Biosciences

I-MAB ( ($IMAB) ) has provided an update. On October 16, 2025, I-Mab announced a strategic transformation to...

2M ago

IMAB

I MAB (ADS) trading resumes

16:25 EDT I MAB (ADS) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

2M ago

IMAB

IMAB FAQ

What was I-Mab Adr’s price range in the past 12 months?

Currently, no data Available

What is I-Mab Adr’s market cap?

Currently, no data Available

When is I-Mab Adr’s upcoming earnings report date?

I-Mab Adr’s upcoming earnings report date is Nov 13, 2025 which is 31 days ago.

How were I-Mab Adr’s earnings last quarter?

I-Mab Adr released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Is I-Mab Adr overvalued?

According to Wall Street analysts I-Mab Adr’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does I-Mab Adr pay dividends?

I-Mab Adr does not currently pay dividends.

What is I-Mab Adr’s EPS estimate?

I-Mab Adr’s EPS estimate is -0.04.

How many shares outstanding does I-Mab Adr have?

Currently, no data Available

What happened to I-Mab Adr’s price movement after its last earnings report?

I-Mab Adr reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Which hedge fund is a major shareholder of I-Mab Adr?

Currently, no hedge funds are holding shares in IMAB